Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Corbus Pharmaceuticals Hldgs Inc (CRBP)
Corbus Pharmaceuticals Hldgs Inc (CRBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,798
  • Shares Outstanding, K 4,215
  • Annual Sales, $ 0 K
  • Annual Income, $ -42,350 K
  • 60-Month Beta 2.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.43
Trade CRBP with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 103.61%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,045.49% on 03/29/23
  • IV Low 0.00% on 06/09/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 7,005
  • Open Int (30-Day) 7,009

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -3.10
  • Number of Estimates 1
  • High Estimate -3.10
  • Low Estimate -3.10
  • Prior Year -2.10
  • Growth Rate Est. (year over year) -47.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.73 unch
on 06/09/23
11.47 -23.89%
on 05/22/23
-0.14 (-1.58%)
since 05/09/23
3-Month
2.11 +313.74%
on 03/10/23
13.17 -33.71%
on 04/19/23
+6.37 (+269.92%)
since 03/09/23
52-Week
2.11 +313.74%
on 03/10/23
13.17 -33.71%
on 04/19/23
-0.21 (-2.35%)
since 06/09/22

Most Recent Stories

More News
Corbus Pharmaceuticals: Q1 Earnings Snapshot

Corbus Pharmaceuticals: Q1 Earnings Snapshot

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals Presents Latest Pre-Clinical Data on CRB-601 at the 2023 American Association for Cancer Research Annual Meeting

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced details of new...

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an...

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals: Q4 Earnings Snapshot

Corbus Pharmaceuticals: Q4 Earnings Snapshot

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update

Company expands precision oncology pipeline with licensing of CRB-701, clinical-stage Nectin-4 antibody drug conjugate (ADC) from CSPC Pharmaceutical Group...

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals Expands Board of Directors with Appointment of Yong Ben, M.D., MBA

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced the appointment...

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)

CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors Clinical development is underway and...

CRBP : 8.73 (-6.33%)
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ selectively within the tumor...

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals: Q3 Earnings Snapshot

Corbus Pharmaceuticals: Q3 Earnings Snapshot

CRBP : 8.73 (-6.33%)
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, today provided a corporate update and...

CRBP : 8.73 (-6.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic...

See More

Key Turning Points

3rd Resistance Point 10.10
2nd Resistance Point 9.82
1st Resistance Point 9.28
Last Price 8.73
1st Support Level 8.46
2nd Support Level 8.18
3rd Support Level 7.64

See More

52-Week High 13.17
Fibonacci 61.8% 8.95
Last Price 8.73
Fibonacci 50% 7.64
Fibonacci 38.2% 6.33
52-Week Low 2.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar